QuanterixQTRX
QTRX
About: Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Employees: 136
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 42
1% more capital invested
Capital invested by funds: $228M [Q1] → $230M (+$2.2M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
9% less funds holding
Funds holding: 149 [Q1] → 135 (-14) [Q2]
21.05% less ownership
Funds ownership: 90.4% [Q1] → 69.35% (-21.05%) [Q2]
31% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 36
53% less call options, than puts
Call options by funds: $7K | Put options by funds: $15K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
8%
upside
Avg. target
$5
8%
upside
High target
$5
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Canaccord Genuity Kyle Mikson | 8%upside $5 | Hold Downgraded | 11 Aug 2025 |
Financial journalist opinion
Based on 9 articles about QTRX published over the past 30 days
Neutral
Business Wire
4 days ago
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanter.
Positive
Zacks Investment Research
2 weeks ago
Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX)
Quanterix (QTRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
Business Wire
2 weeks ago
Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be acc.
Neutral
Seeking Alpha
2 weeks ago
Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Joshua Young - Corporate Participant Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Michael Aaron Cherny - Leerink Partners LLC, Research Division Thomas DeBourcy - Nephron Research Operator Good day, everyone, and thank you for standing by. My name is [ RJ ], and I will be your conference operator today.
Negative
Zacks Investment Research
2 weeks ago
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.25 per share a year ago.
Neutral
Business Wire
2 weeks ago
Quanterix Releases Financial Results for the Second Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market,” said Masoud Toloue, CEO of Quanterix. “We have built a franchise that is gen.
Neutral
Business Wire
3 weeks ago
Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. E.T., to discuss its second quarter 2025 financial results. Quanterix will issue a press release regarding its second quarter 2025 financial results prior to the conference call on Thursday, August 7, 2025, after the market closes. The press release.
Neutral
Business Wire
3 weeks ago
Quanterix Announces Cooperation Agreement with Kent Lake Capital
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has entered into a cooperation agreement (the “Agreement”) with Kent Lake Partners LP (together with its affiliates, “Kent Lake”). The Company has committed to appointing a new independent director by December 1, 2025. The new director will be identified through a comprehensive search pr.
Neutral
Business Wire
4 weeks ago
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (.
Neutral
Business Wire
1 month ago
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units (“RSUs”) representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasd.
Charts implemented using Lightweight Charts™